SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?


To: DanZ who wrote (4913)11/13/2003 9:13:30 AM
From: StockDung  Respond to of 5582
 
TRUTHSEEKER FTC/FDA MOST EXCELLENT ADVENTURE
------------------------------------------

FDA CALLED ME. LAST FRIDAY

MR. SZYMANSKY OF FDA ASKED ME TO SEND THE ADDITIONAL INFORMATION TO THE FOLLOWING ADDRESS. ATTENTION MS. SILVER. PRIOR TO THIS THE FTC HAD CALLED ME. IT WAS INTERESTING THAT FTC ALREADY WHERE ALERTED ABOUT ZICAM BECAUSE ON INFO ON THE QUACKWATCH WEB SITE. I HAD FAXED MICHELLE RUSK OF QUIGLEY FAME SOME PRELIMINARY INFO WITH THE REST TO FOLLOW. THE FTC IS THE ONE THAT SENT MY ORIGIONAL INFO TO THE FDA. MR. MILLER OF FTC SAID FDA MAY BE CALLING ME AND THEY DID

U.S. DRUG AND FOOD ADMINISTRATION
CENTER FOR DRUG EVALUATION AND OFFICE OF COMPLIANCE
ATTEN: LINDA SILVER (team leader internet group)
5600 FISHER LANE
ROCKVILLE MD 20857

I URGE ALL TO SEND ANY INFO YOU HAVE ON ZICAM TO THEM.

AND JUST ONE MORE THING.

BECAREFUL WHO YOU SLAPP

Does he love me I want to know
How can I tell if he loves me so
Is it in his eyes ?
Oh no ! You'll be deceived
Is it in his sighs ?
Oh no ! He'll make believe
If you want to know if he loves you so
It's in his kiss
That's where it is

Is it in his face ?
Oh no ! That's just his charms
In his warm embrace ?
Oh no ! That's just his arms
If you want to know if he loves you so
It's in his kiss
That's where it is
It's in his kiss
That's where it is

Kiss him and squeeze him tight
Find out what you want to know
If it's love, if it really is
It's there in his kiss



To: DanZ who wrote (4913)11/13/2003 10:31:23 AM
From: StockDung  Respond to of 5582
 
ANOTHER REALLY REALLY FAMOUS DAN QUOTE!

"To rephrase my comment: Anyone that calls Zicam Cold Remedy "caustic", or "acidic" because it is a zinc salt does not know what they are talking about."

IS THAT RIGHT? YOU WERE WRONG WHEN YOU SAID THAT ZINC GLUCONATE IS NOT A ZINC SALT. AND SOON YOU WILL SEE WHY IT IS JUST AS DANGEROUS TO THE NOSE AS INTRANASAL ZINC SULFATE. SPIN IT HOWEVER YOU WANT. TELL ME THAT
THESE DOCTORS AND RESEARCHERS WERE WRONG. THEY WERE THERE AND THEY FOUND OUT THE HARD WAY BY PUTTING TOXIC/CAUSTIC ZINC IONS DIRECTLY ON
THE OLFACTORY AREA OF HUMANS.

REPEATED FOR DAN, "BY PUTTING TOXIC/CAUSTIC ZINC IONS DIRECTLY ON THE OLFACTORY AREA"

June 26, 1937 Vol 108 #26 JAMA Journal of American Medical Association

THE CHEMICAL PROPHYLAXIS FOR POLIOMYLELITIS: THE TECHNIC OF APPLYING
ZINC SULFATE INTRANASALLY

June 26, 1937 Vol 108 #26

By Max Peet M.D. Dean Echols M.D. Harry Richter M.D.

"Zinc sulfate has long been used in diseases of the eye and nose with out a single instance of serious harm resulting. With such a weak
solution as 1 per cent, the strength recommended for nasal instillation
and in the small quantity used, we feel certain that no serious sequelae (after-effect of injury) will result. However, it was found
that when zinc sulfate was actually applied to the olfactory area, it produced a severe burning or smarting sensation with coryza (nasal mucus) and in most subjects a severe headache, which lasted for several
hours. Zinc sulfate introduced into the lower portions of the nose does not produce such symptoms. It is only when it is applied to the
olfactory area that this pain results."

LAST TWO SENTENCES REPEATED FOR DAN.

"Zinc sulfate introduced into the lower portions of the nose does not produce such symptoms. It is only when it is applied to the olfactory area that this pain results."

IN CASE YOU DIDN'T KNOW, THEY BOTH CONTAIN ZINC IONS.



To: DanZ who wrote (4913)11/13/2003 10:14:36 PM
From: StockDung  Respond to of 5582
 
straightdope=>Can zinc lozenges cure the common cold?
Week of: 06-Feb-98

web.archive.org

--------------------------------------------------------------------------------


Dear Cecil:

Why are people bothering with getting colds any more? The site web.archive.org has been around for a couple years now and the product for stopping common cold symptoms is available in many places (Wal-Mart for one). Could you check out that site and apply your skills to either (1) debunk it or (2) confirm it?

I first read about the "cure" in the 1980s in one of the science news magazines. As long as I used it at the first signs of a cold, it went away the same day. Now that the discoverer has a decent-tasting formulation, it is not only effective but palatable. It is astounding that now that there is a "cure for the common cold," so few people acknowledge it. I do not believe in authority or anecdotes, but this "cure" has clinical studies behind it. What gives with the ignorance? --William Hathaway, via the Internet

Cecil replies:

Your columnist wants a cold cure as much as the next guy, William. (Sniffle.) But let's look at this objectively. Somebody announces Surefire Cold Cure number 1,000. Previous attempts have gone 0-for-999. (Hack, wheeze.) You believe this one's different. The rest of the world evidently doesn't (although the thing has gotten loads of publicity). You may think you've got a better grasp of the science, but the world's got a better grasp of the (honk) odds.

The cure we're talking about is sucking on zinc lozenges. George Eby, who came up with the idea and runs the Web site you mentioned, is currently big on the benefits of zinc acetate, but other formulations such as zinc gluconate are also popular. One brand of pill combines zinc with echinacea, a plant extract touted for its antiviral properties. Might as well wash it down with some chicken soup--a lot of people still believe in that, too.

Here's the story to date:

1979: George Eby's three-year-old daughter starts coming down with a cold. Since her immune system has been suppressed following leukemia treatment, he fears that she's in for a nasty one. She sucks on a zinc pill. Two hours later her symptoms have vanished. Whoa, thinks George. He begins researching zinc's curative powers.

1984: Eby and associates report in a medical journal that sucking on zinc gluconate lozenges signicantly reduced the average duration of cold symptoms in a group of 65 patients. Other researchers subsequently report similar results.

Skeptics are quick to attack. Among other criticisms, they claim zinc lozenges have a distinctively yucky taste that may have skewed the results. One study notes sarcastically: "The significant reduction in the duration of common colds with zinc gluconate lozenges ... may be due to ... the subjects' belief that anything tasting as bad as zinc and with as much aftertaste as zinc must be good medicine" (Farr and Gwaltney, 1987).

A related possibility: patients were disinclined to report a recurrence of cold symptoms for fear they'd have to resume taking those god-awful pills. Several subsequent studies that try to minimize the problem of taste (for example, by making sure the placebo used as a control tastes equally bad) find that zinc lozenges have little or no effect on colds.

Zinc advocates don't give up. They argue that the lozenges used in the negative studies were of a type that inactivated the zinc.

1996: A team of researchers at the Cleveland Clinic Foundation publish a study claiming that patients who took zinc gluconate lozenges got over their colds in 4.4 days on average, compared to 7.6 days for patients taking a placebo. The antizinc camp objects that the Cleveland study has fallen into the same trap as the Eby study--the subjects could tell which lozenges contained zinc, so their responses were biased. Were not, the Cleveland researchers riposte. But their conclusions are based mostly on the testees' personal assessment of their symptoms rather than on objective clinical measures, which doesn't give you much confidence.

Further complicating matters is the revelation that prior to publishing their study (but after completing their research) two Cleveland scientists bought stock in a company selling zinc lozenges. The stock of the company rose substantially when the study results were publicized.

So, am I skeptical? I'm always skeptical. There have been only a handful of zinc studies, involving small numbers of patients and yielding contradictory results. (Current score: four studies say it works, four say it doesn't.) A similar situation arose 20 years ago, only the cold cure in question was vitamin C. That controversy ended indecisively, and today you don't hear much about vitamin C as a cold cure. I'll bet you a jumbo box of Contac that the same thing happens to zinc.

--CECIL ADAMS

--------------------------------------------------------------------------------

[ Next Week | Recent Columns Index | Previous Week ]

--------------------------------------------------------------------------------

The Straight Dope / Questions or comments for Cecil Adams to: cecil@chireader.com
Comments regarding this website to: webmaster@straightdope.com
Copyright © 1996, 1997, 1998 Chicago Reader, Inc. All rights reserved.
No material contained in this site may be republished or reposted without express written permission.
The Straight Dope is a registered trademark of Chicago Reader, Inc.

This page last modified Sat, Feb 14, 1998.



To: DanZ who wrote (4913)11/15/2003 2:49:55 PM
From: StockDung  Respond to of 5582
 
COURT MEMORANDUM. ATTENTION ALL SCHMEXPERTS!

pucker_uppppppp SAID:

"You aren't suppose to snort it. if you follow the directions IT STAYS IN THE BOTTOM PART OF THE NOSE. I've never had a problem w/ it. the most that may come out of this lawsuit will be an addition of a warning to the package about snorting it up your nose."

SO MUCH FOR THE DIRECTIONS, PUCKER. HEY, ALL YOU OTHER SCHMEXPERTS OUT THERE. WHEN USED AS DIRECTED, I THOUGHT YOU SAID THIS NEVER HAPPENS!

READ COURT MEMORANDUM BELOW AND WEEEEEEEEP. DON'T SNIFF TOO HARRD.
HO HO HO HE HE HE HA HA HA!

BECAREFUL WHO YOU SLAPP

Quigley Corp. v. GumTech, Inc. Patent Infringement March, 2000

MEMORANDUM

"On this evidence, and although it is a close case, we find that Quigley has demonstrated a likelihood of success in proving infringement. It would seem clear from Dr. Goldberg's testimony that when Zicam is used as directed, at least some of the product reaches the throat."

"Dr. Goldberg testified that he had performed an experiment in which a healthy twenty-nine year old male had used Zicam according to the directions on the package and Dr. Goldberg then observed the subject's nose and throat. Immediately after use, Dr. Goldberg could see the Zicam in the subject's nose, and as time passed the subject reported feeling it in the back of his nose. At eleven minutes after use, the subject could still feel the Zicam in the back of his nose and Dr. Goldberg was able to see some Zicam, which has a white-like color, on the back of the palate at the uvula and at the very back of the mouth. At twelve minutes after use, Zicam was visible on the oropharynx -- that is, in the throat."

"For the defense, Dr. Riley offered his opinion that Zicam is designed and intended to remain in the nose, for it is in the nasal cavity that the main antiviral effect is accomplished. He noted that the lining of the nasopharynx, located behind the nasal cavity and above the throat, is physically distinct from the lining of the throat and is most susceptible to the rhinovirus; thus Zicam is made to attack the rhinovirus in the area where it is most likely to infect a human. He also testified that while Zicam’s gel base may travel past the nose and down the throat, the zinc is given up in the nose.



To: DanZ who wrote (4913)11/15/2003 8:47:42 PM
From: StockDung  Respond to of 5582
 
United States Patent 6,365,624
Davidson , et al. April 2, 2002
Method and composition for delivering zinc to the nasal membrane

Abstract

A viscous gel for delivering minor effective homeopathic amount of zinc or another metal to the nasal membrane.

Inventors: Davidson; Robert S. (Woodland Hills, CA); Hensley; Charles (Redondo Beach, CA); Kehoe; Gary S. (Glendale, AZ)
Assignee: Gel Tech, L.L.C. (Woodland Hills, CA)
Appl. No.: 603864
Filed: June 26, 2000
Current U.S. Class: 514/494; 424/400; 424/434; 424/489; 514/849; 514/944
Intern'l Class: A61K 031/315
Field of Search: 424/400,434,489 514/494,849,944

References Cited [Referenced By]

U.S. Patent Documents

4503070 Mar., 1985 Eby, III.
4686528 Aug., 1987 Godfrey.
4758439 Jul., 1988 Godfrey.
4956385 Sep., 1990 Eby, III.
RE33465 Nov., 1990 Eby, III.
5002970 Mar., 1991 Eby, III.
5095035 Mar., 1992 Eby, III.
5286748 Feb., 1994 Eby, III.
5409905 Apr., 1995 Ebby, III.
5622724 Apr., 1997 Bryce-Smith.

Other References

Gutman (1941) Modern Drug Encyclopedia, 1941, P. 731.
Aug. 24, 1998 Response to Office Action (Pat. No. RE 33,465).

Primary Examiner: Clardy; S. Mark
Assistant Examiner: Williamson; Michael A.
Attorney, Agent or Firm: Snell & Wilmer L.L.P.

Parent Case Text

This is a Continuation of U.S. application Ser. No. 09/145,042, filed Sep. 1, 1998 now U.S. Pat. No. 6,080,783.

Claims

We claim:

1. A method of delivering zinc to a nasal membrane, the method comprising the steps of:

providing a zinc composition having a viscosity between about 5,000 and about 20,000 centipoise; and

applying said composition to a nasal cavity.

2. The method of claim 1, wherein said applying step includes supplying about 1 ounce of said composition to the nasal cavity.

3. The method of claim 1, wherein said applying step includes spraying said composition into a portion of a nasal cavity.

4. The method of claim 1, wherein said applying step includes supplying a zinc composition having a zinc concentration in the range of about 15 mM to about 40 mM.

5. The method of claim 1, wherein said applying step includes supplying a zinc composition having a zinc gluconate concentration in the range of about 0.9 to about 2.0 weight percent.

6. A method of reducing a duration of a common cold symptom, the method comprising the steps of:

providing a zinc gel composition including about 0.9 to about 2.0 weight percent zinc gluconate; and

applying said composition to a nasal membrane.

7. The method of claim 6, wherein said applying step includes spraying said composition.

8. The method of claim 6, wherein said applying step includes providing zinc ions configured to bind to viral ICAM-1 receptors.

9. A composition for reducing a duration of a common cold comprising:

about 90 to about 99.1 weight percent of a carrier; and

about 0.9 to about 2.0 weight percent zinc gluconate,

wherein said composition has a viscosity greater than about 5,000 centipoise.

10. The composition of claim 9, wherein said carrier includes glycerin.

11. The composition of claim 10, wherein said carrier includes about 0.05 to about 3.0 weight percent glycerin.

12. The composition of claim 9, further comprising a thickener.

13. The composition of claim 12, wherein said thickener is selected from the group consisting of: carbohydrate thickeners, carrageenan, sugar, guar gum, and methylcellulose.

14. The composition of claim 9, further comprising about 0.01 to about 0.10 weight percent methanol.

Description

This invention relates to compositions and method for delivering minor effective amounts of a metal to the blood in a body.

More particularly, the invention relates to a method and composition for delivering a minor effective amount of ionic zinc to the nasal membrane.

In a further respect, the invention relates to a composition which maintains zinc in a negative ionic state for delivery to the nasal membrane.

In another respect, the invention relates to a composition which maintains a source of a metal in direct contact with the nasal membrane for an extended period of time.

The common cold is one of the most frequently occurring human illnesses and is responsible for substantial morbidity and economic loss. Ionic zinc is a known effective anti-rhinovirus agent in vitro and in vivo.

In one in vivo study reported in 1991, a double-blind clinical trial demonstrated the effectiveness of orally administered zinc gluconate/glycerine lozenges. The lozenges used in the study contained twenty-three milligrams of zinc provided by 179 milligrams of zinc gluconate trihydrate which provided a 13.1 millimolar ionic zinc concentration in the oral cavity. During the study, lozenges administered at two hour intervals resulted in a forty-two percent reduction in mean cold duration and in a marked reduction in both the number and severity of symptoms if treatment with the lozenges was initiated within two days of the onset of cold symptoms. A second study reported in 1992 (Zarmebo J. E., Godfrey J. C., Godfrey N., J. Pharmm Sci 1992; 81: 128-130) confirmed the findings of the 1991 study. Soon after the results of these studies became widely known, a number of companies began marketing their own versions of the zinc lozenge cold remedy.

While zinc lozenges are usually beneficial in treating a cold, the lozenges have several drawbacks. First, the majority of zinc in a zinc gluconate lozenge is released in the oral cavity. The principal site, however, of antiviral activity is believed to be the nasal cavity (Novick S. G., Godfrey J. C., Godfrey N. J., Wilder H. R., Medical Hypothesis 1996; 46: 295-302). It is surmised that some ionic zinc released by a lozenge in the oral cavity makes its way to nasal passages where the zinc binds to viral ICAM-1 receptors and inhibits rhinovirus from binding to and infecting nasal mucosal cells. The difficult encountered by ionic zinc in attempting to travel from the oral cavity to the nasal cavity limits the effectiveness of zinc lozenges. Further, in a congested individual the route from the oral cavity to the nasal cavity may be completely blocked, rendering zinc lozenges ineffective.

A second disadvantage associated with zinc lozenges is production of significant side effects. In one study, twenty percent of the subjects complained of nausea and eight percent complained of bad taste reactions (Novick S. G., Godfrey J. C., Godfrey N. J., Wilder H. R., Medical Hypothesis 1996; 46: 295-302). With respect to the nausea, it is well established that excessive zinc in the intestinal tract interferes with copper absorption and that preventing the absorption by the body of sufficient quantities of copper can lead to a variety of undesirable pathological states. The overuse of zinc lozenges may contribute to copper depletion.

We have discovered a novel composition and method for delivering ionic (negatively charged) zinc to the nasal membrane without encountering the disadvantages normally associated with zinc lozenges. The composition maintains ionic zinc in direct contact with the nasal membrane, preferably for an extended period of time of at least one-quarter hour, and delivers rapidly zinc into the nasal membrane and into blood in the nasal membrane. The composition includes from 90% to 99.1 by weight of at least one carrier and 0.9% to 2.0% by weight (from about 20 mM to 44 mM), preferably 0.9% to 1.5% (from about 20 mM to 33 mM), zinc gluconate. Each 0.1% by weight zinc gluconate in the composition produces a concentration of approximately 0.014% by weight ionic zinc (i.e., of about 2.2 mM ionic zinc). At least a 20 mM concentration of ionic zinc is preferred in the composition to insure that a sufficiently high concentration of ionic zinc is produced by the composition at the interface between the composition and the nasal membrane.

The composition has a viscosity in the range of 5,000 to 20,000 centipoise. The viscosity of the composition is important because it facilitates maintenance of the composition in the nasal cavity in contact with the nasal membrane or with mucous on the membrane. When the viscosity is less than about 5,000 centipoise, the composition tends to be drawn by gravity out of the nasal cavity. If the viscosity is in excess of about 20,000 centipoise, the thickness of the composition interferes with the diffusion of ionic zinc through the composition to the nasal membrane. During the development of the composition of the invention, nasal sprays were considered and discarded because the low viscosity of the liquids comprising such sprays allows the liquids to flow under gravity out of the nasal cavity, preventing the sprays from contacting the nasal membrane for an extended period of time. The effectiveness of a nasal spray usually substantially dissipates in less than five minutes. Similarly, applying the composition on a swab or nose plug is not believed efficient because the swab or nose plug, which may for example be made of cotton or of a sponge material retains the composition and interferes with the delivery of an additional supply of the composition into contact with the nasal membrane following dissipation of the composition which is on the surface of the swab or plug and is in direct contact with the nasal membrane.

As noted, nasal sprays were avoided during development of the invention. By way of background with respect to zinc--bearing nasal sprays, U.S. Pat. No. 5,688,532 concerns antiallergic spray preparations and discloses and claims a method for the treatment of an allergic condition in which a spray solution is applied to the eye or respiratory tract of a mammal having the allergic condition. The spray solution includes a non-toxic, anti-allergy effective amount of ionic zinc in a concentration below that which causes irritation to mucus membranes. The majority of the ionic zinc in the spray solution is unchelated zinc and is in the form of free ionic solution, wherein the solution has a zinc ion content of between about 0.002 and about 0.12% (w/v). The allergic condition treated with the spray solution can comprise hay-fever and asthma. The spray solution can be selected from the group consisting of essentially aqueous and essentially saline solutions; can have a zinc ion content of about 0.04% (w/v); can comprise a mineral acid salt of zinc as solute; can comprise a solute selected from the group consisting of zinc sulfate and zinc chloride; can be dispensed in aliquots of about either 0.05 to 0.5 ml or 0.2 ml; and/or, can include at least one other pharmaceutically acceptable ingredient. The other pharmaceutically acceptable ingredient can be selected from the group consisting of antihistamines, scenting agents and active ingredients; or, can comprise ascorbate. U.S. Pat. No. 5,688,532 also discloses and claims an improvement in a method for treatment of an allergic condition by the administration of a zinc compound to a mammal possessed of an allergic condition. The improvement consists essentially of spraying a solution comprising a non-toxic, anti-allergy effective amount of ionic zinc to the eye or respiratory tract of a mammal possessing the allergic condition. The solution comprises a concentration of ionic zinc below that which causes irritation to mucus membranes. The majority of the ionic zinc in the spray is unchelated zinc and is in the form of free ionic solution. The solution has a zinc ion content of between about 0.002 and 0.12% (w/v). U.S. Pat. No. 5,622,724 discloses and claims a method for the treatment of the symptoms of the common cold comprising administering a spray of a solution containing a non-toxic, symptom effective treating amount of a solution of a substantially unchelated ionic zinc compound. The solution contains substantially unchelated zinc ions in a concentration of from about 0.004 to about 0.12% (w/vol), to the nostrils and respiratory tract of a patient in need thereof. The solution can be selected from the group consisting of aqueous and saline solutions; can further comprise an effective amount of a flavor and/or odor enhancing agent; can have an unchelated zinc ion content of about 0.04% (w/v); or, can consist essentially of the substantially unchelated ionic zinc compound and at least one pharmaceutically acceptable carrier. The substantially unchelated ionic zinc compound can comprise a mineral acid salt of zinc; can comprise a salt selected from the group consisting of zinc sulfate and zinc chloride; or, can comprise zinc sulfate. Utilization of zinc chloride at concentrations greater than 0.2%, especially greater than 0.4% is not preferred because, as is well known in the art, zinc chloride is caustic.

The carrier utilized in the invention can include 0.05% to 3.0% by weight glycerine. The glycerine is important and is presently preferred because it allows zinc to remain in a negative ionic state until the zinc contacts the nasal membrane and/or mucous on the nasal membrane. One problem encountered during development of the invention was identifying a carrier which maintains zinc in an ionic state.

The composition of the invention preferably permits ionic zinc to diffuse through the composition to the nasal epithelial membrane or mucous on the epithelial membrane. This facilitates the availability of a continuous supply of ionic zinc because the composition will continue via diffusion to supply zinc without requiring that the portion of the composition adjacent the nasal epithelial membrane (on mucous on the membrane) dissolve or dissipate and expose a fresh portion of the composition containing ionic zinc. As noted, composition viscosities in excess of about 20,000 centipoise are believed to interfere with the diffusion of zinc through the composition. Viscosity measurements recited herein were obtained using the Brookfield Syncho-Lectric Viscometer for the measurement of the apparent Viscosity of Newtonian and Non-Newtonian materials at low shear rates at given rotational speeds (ASTM D1824-87). Spindle 4 for a viscosity less than 8,000 centipoise; spindle 6 or a viscosity of 8,000 centipoise or greater. See also ASTM D1084-88, ASTM D2196-86 and other ASTM protocols concerning the measurement of viscosity.

We have also discovered a method of delivering minor effective amounts of a metal into the blood. The method includes the step of providing a viscous delivery composition. The delivery composition includes 90% to 99.995% by weight of at least one carrier and less than 1.5% by weight of the metal. The composition has a viscosity in the range of 5,000 to 20,000 centipoise. The method includes the additional steps of applying the delivery composition in the nasal cavity in direct contact with the nasal membrane, and maintaining the delivery composition in contact with the nasal membrane for at least one-quarter hour.

The following examples depict the presently preferred embodiments of the invention for the purposes of illustrating the practice thereof and not by way of limitation of the scope of the invention. In the examples, all proportions are by weight, unless otherwise noted.

EXAMPLE 1

One thousand ounces of a zinc gel is prepared by mixing together purified water, glycerin, carbopol, and zinc gluconate. The gel includes: Component Weight Percent
PURIFIED WATER 95.8
GLYCERIN U.S.P 2.0
CARBOPOL 940 nf 0.5
ZINC (IONIC) 0.21 (33.3 mM)
ZINC GLUCONATE (source of ionic zinc) 1.50 (33.3 mM)

The concentration of zinc gluconate in the gel composition of the invention is preferably in the range of 0.9% to 2.0% (20 mM to 44 mM), preferably 0.9% to 2.0%, by weight. The carrier in the gel composition can vary as desired, but presently preferably includes 90.0 to 99.0% purified water, 0.05 to 3.0% by weight glycerine (a thickener which also functions to permit zinc to maintain its ionic state), and 0.5% to 3.0% by weight of a carbohydrate or other thickener. A carbohydrate thickener is presently preferred. Other thickeners which can be utilized include: carrageenan, sugar, guar gum, and methylcellulose. The glycerine in the carrier produces a matrix which permits zinc ions to readily diffuse therethrough. The glycerine is also preferred because it has the ability to dissolve into and permeate mucous and the nasal epithelial membrane, carrying with it ionic zinc.

EXAMPLE 2

One ounce of the zinc gel of Example 1 is placed in the nasal cavity of a healthy thirty-nine year old male Caucasian. The gel remains in contact with at least a portion of the nasal epithelial membrane or the mucous layer on the membrane. After four hours the zinc gel has completely dissipated.

EXAMPLE 3

Example 2 is repeated, except the individual is a twenty-four year old African American who has been experiencing mild cold symptoms for one day. The gel remains in contact with at least a portion of the nasal epithelial membrane or the mucous layer on the membrane. After four hours the zinc gel has completely dissipated and the individual notices a marked reduction in the severity of his cold symptoms.

EXAMPLE 4

Example 3 is repeated, except that the zinc gel of the invention is not administered to the twenty-four year old African American, nor is any other medication. After four hours, he does not notice any reduction in the severity of his cold symptoms.

EXAMPLE 5

Examples 3 and 4 are repeated, except the individual treated is a fifteen year old Japanese girl who has been suffering from mild cold symptoms for a day. Similar results are obtained.

EXAMPLE 6

Examples 3 and 4 are repeated, except the individual treated is a fifty year old Caucasian man who has been suffering from cold symptoms for two days. Similar results are obtained.

EXAMPLE 7

Example 2 is repeated except that the concentration of zinc in the nasal mucosa is measure just prior to insertion of the zinc gel; and, one, two, three, and four hours after the gel is inserted in the individual's nasal cavity. The following results are obtained: Time of Measurement Zinc Concentration (Wt. %)
Just prior to administration 0.003%
of zinc gel
Ten minutes after administration 0.008%
of zinc gel
One-half hour after administration 0.01%
of zinc gel
One hour after administration 0.01%
of zinc gel
Two hours after administration 0.011%
of zinc gel
Three hours after administration 0.012%
of zinc gel
Four hours after administration 0.012%
of zinc gel

EXAMPLE 8

Examples 1 to 6 are repeated, except that the concentration of ionic zinc in the composition is 20 mM instead of 30.0 millimolar. Similar results are obtained.

EXAMPLE 9

Example 1 to 6 are repeated, except that the concentration of ionic zinc in the composition is 44 mM instead of 30.0 millimolar. Similar results are obtained.

EXAMPLE 10

Examples 1 to 6 are repeated, except that the concentration of ionic zinc in the composition is 33 mM instead of 15.0 millimolar. Similar results are obtained.

One of the objectives of the invention is the delivery into the blood via the nasal membrane homeopathic concentrations of metals or other chemical elements or compositions. This ordinarily requires the delivery of specific selected titrated concentrations (i.e., minor effective amounts) of a component. If a component is delivered to the blood stream in a concentration which is too high, this can have an inadverse effect in the body. The delivery of minor effective amounts of components to the blood stream via the nasal membrane in accordance with the invention is believed highly advantageous because it offers a rapid delivery into the blood stream of selected metered minor effective amounts of a metal or other chemical element(s) or composition(s). Attempting to deliver orally homeopathic titrated amounts of chemical elements or compositions is not believed practical because of the degradation of chemical elements which occurs in the oral cavity.

Zinc in the nasal cavity acts as a decongestant, enhancing the discharge of mucous and inhibiting the generation of new mucous. Menthol is also a decongestant and can be incorporated in the composition of the invention in a concentration of 0.01% to 0.10% by weight. Menthol is a bronchial dilator, functioning to open air passages in the lungs and to help discharge mucous.

When the zinc gel of the invention is applied to the nasal cavity, zinc ions diffuse from the gel matrix into the mucous or mucous membrane in the nasal cavity. It is believed that the zinc concentration in the mucous or mucous membrane creates a barrier which inhibits viral infection of the nasal epithelial membrane. As ionic zinc is absorbed from the gel into the mucous membrane and other nasal epithelial cells, the gel matrix permits new zinc to diffuse into the nasal membrane. The gel matrix has micelle cell--like properties which facilitate the diffusion of zinc through the gel matrix.

The homeopathic concentration of zinc ions in the zinc gel of the invention is 20 millimolar (mM) to 44 millimolar, preferably 20 mM to 33 mM. Concentrations of zinc in excess of 44 mM are not preferred.

As would be appreciated by those of skill in the art, various carriers can be developed to deliver any desired metal, pharmaceutical, or other chemical element or component into the blood stream via the nasal membrane, either in homeopathic or other desired concentrations.

Having described our invention in such terms as to enable those skilled in the art to understand and practice it, and having identified the presently preferred embodiments thereof.



To: DanZ who wrote (4913)11/15/2003 8:55:05 PM
From: StockDung  Respond to of 5582
 
Attorney, Agent or Firm: Snell & Wilmer L.L.P.



To: DanZ who wrote (4913)11/16/2003 12:33:34 PM
From: StockDung  Respond to of 5582
 
Nasal Toxicity, Carcinogenicity, and Olfactory Uptake of Metals
F. William Sunderman, Jr.
Department of Chemistry and Biochemistry, Middlebury College, Middlebury, Vermont, and Department of Pathology, College of Medicine, University of Vermont, Burlington, Vermont

Abstract. Occupational exposures to inhalation of certain metal dusts or aerosols can cause loss of olfactory acuity, atrophy of the nasal mucosa, mucosal ulcers, perforated nasal septum, or sinonasal cancer. Anosmia and hyposmia have been observed in workers exposed to Ni- or Cd-containing dusts in alkaline battery factories, nickel refineries, and cadmium industries. Ulcers of the nasal mucosa and perforated nasal septum have been reported in workers exposed to Cr(VI) in chromate production and chrome plating, or to As(III) in arsenic smelters. Atrophy of the olfactory epithelium has been observed in rodents following inhalation of NiSO4 or aNi3S2. Cancers of the nose and nasal sinuses have been reported in workers exposed to Ni compounds in nickel refining, cutlery factories, and alkaline battery manufacture, or to Cr(VI) in chromate production and chrome plating. In animals, several metals (eg, Al, Cd, Co, Hg, Mn, Ni, Zn) have been shown to pass via olfactory receptor neurons from the nasal lumen through the cribriform plate to the olfactory bulb. Some metals (eg, Mn, Ni, Zn) can cross synapses in the olfactory bulb and migrate via secondary olfactory neurons to distant nuclei of the brain. After nasal instillation of a metal-containing solution, transport of the metal via olfactory axons can occur rapidly, within hours or a few days (eg, Mn), or slowly over days or weeks (eg, Ni). The olfactory bulb tends to accumulate certain metals (eg, Al, Bi, Cu, Mn, Zn) with greater avidity than other regions of the brain. The molecular mechanisms responsible for metal translocation in olfactory neurons and deposition in the olfactory bulb are unclear, but complexation by metal-binding molecules such as carnosine (b-alanyl-L-histidine) may be involved. (received 2 October 2000; accepted 16 November 2000). Ann Clin Lab Sci 2001, 31:3-24.

Keywords: Rhinotoxicity, anosmia, nasal perforation, sinonasal cancer, olfactory nerve, olfactory bulb, aluminum, arsenic, bismuth, cadmium, chromium, cobalt, copper, mercury, manganese, nickel, zinc



To: DanZ who wrote (4913)11/16/2003 12:35:20 PM
From: StockDung  Respond to of 5582
 
<BDisorders of olfaction are infrequent but a complete loss of smell reduces the quality of life significantly. The perceptions of smell and taste are often combined. Taste only differentiates four qualities: sweet, sour, salty, and bitter. Olfaction is the sense that brings you all those wonderful flavors in between that you find in food and drink. Without smell you wouldn't be able to tell the difference between a piece of strawberry candy and grape candy; it would only be sweet with no distinction of actual flavor.

macalester.edu



To: DanZ who wrote (4913)11/16/2003 12:56:01 PM
From: StockDung  Respond to of 5582
 
Interesting 

Message 19505306

It seems  improbable that the all the zinc would have dissipated or would have been selectively absorbed before it reached the back of the throat or oropharynx....

the olfactory receptor cells leading to the olfactory bulb are along this path

macalester.edu

driesen.com

images.google.com

images.google.com



To: DanZ who wrote (4913)11/16/2003 1:00:35 PM
From: StockDung  Respond to of 5582
 
Patients with olfactory disorders need to take special precautions:

1. Install multiple smoke alarms in the home.
2. Change from natural gas appliances to electric.
3. Clearly mark expiration dates on food.
4. Enlist the help of friends and family in issues
of social concern.

utmb.edu



To: DanZ who wrote (4913)11/16/2003 6:18:43 PM
From: StockDung  Respond to of 5582
 
MORE COMPANIES TO RESEARCH swlaw.com



To: DanZ who wrote (4913)11/16/2003 6:32:58 PM
From: StockDung  Respond to of 5582
 
Kevin Parker Areas of practice include real estate litigation and zoning, probate & trust litigation, and business and commercial litigation.

EDUCATION
University of Michigan (J.D., magna cum laude, 1985; B.B.A., magna cum laude, 1982)
Law Review
Order of the Coif
Award for highest score on Arizona state bar examination (July 1985)

COURT ADMISSIONS
Supreme Court of Arizona (1985)
United States Court of Appeals, Ninth Circuit (1985)
United States District Court, District of Arizona (1985)

PROFESSIONAL MEMBERSHIPS AND ACTIVITIES
Arizona Association of Defense Counsel
State Bar of Arizona
Civil Practice and Procedure Committee (1996-1999 term)
Trial Practice Section
Appellate Section
Probate and Trust Section
Mental Health and Elder Law Section
Maricopa County Bar Association
Estate Planning, Probate and Trust Section
Arizona Bar Foundation, Fellow

swlaw.com



To: DanZ who wrote (4913)11/18/2003 10:48:04 AM
From: StockDung  Respond to of 5582
 
Interesting that Dan Zimmerman accuses the Matrixx of fraud by low-balling guidence. Is the real number, say 35 cents being whispered on the street? If Dan is correct this would clearly be a violation of Sarbanes-Oxley act. Not often that analyst Dan Zimmermann bashes the MTXX but appears exactly what he did.
--------------------------------------

"I think that Matrixx is low-balling their guidance so they can beat it."

To:Ron McKinnon who wrote (49261)
From: Dan Zimmermann Wednesday, Sep 24, 2003 7:41 AM
View Replies (2) | Respond to of 49638

Ron,Here's what I think the market is seeing. Matrixx said that they expect revenue growth of at least 30% for each of the next two years. They also said to expect R&D expense about 6% of sales to develop new products, and that last year's operating expenses, which includes advertising, is about what it needs to be to meet the company's sales targets. It doesn't take a rocket scientist to plug these numbers into a spreadsheet and calculate earnings estimates for each of the next two years. The company is putting out much better guidance now, and if they just meet it the stock is worth more.

I think that Matrixx is low-balling their guidance so they can beat it. Sales were up 76% in the first two quarters this year over the same period last year. Sales of existing products grew about 30% year over year, and the rest of the growth came from new products released last September (primarily Zicam Swabs). Matrixx is launching three new oral products this cold season, so it would be virtually impossible for them to grow sales only 30% year over year. For that to occur, sales of existing products would have to decline and sales of the three new oral products would have to be zero. Based on information in recent company press releases, it is obvious this isn't the case and that sales will grow much more than 30% this year. Gross margin should also improve in 2004 back to the more typical 70% to 72%. Matrixx settled their law suit with Zila and is contracting with a new manufacturer that will make swabs for even less than Zila charged before unilaterally increasing the cost early this year. Additional new products in 2004, most likely in the pain relief market (analgesic), will contribute to next year's growth.

If Matrixx increases sales 40% this year (conservative view in my opinion), the company would earn about 30 cents per share, or more than 100% above last year's earnings of 14 cents per share. If sales grow another 40% in 2004, the company would earn 60 to 70 cents per share in 2004, which equates to about 130% growth in earnings. While those numbers might seem high to the casual observer, the number of shares outstanding has remained relatively constant at 9.5 million the last two years and Matrixx has finally exceeded their break even point with growing sales of existing products and new products being released relatively quickly. The company released five new products last September and three new products this quarter. Matrixx has a lot of earnings leverage due to the small number of shares outstanding, high gross margin of about 70%, and cost structure which is primarily variable. The company's fixed expenses are low when compared to sales expectations.

At least two new funds bought shares in MTXX last quarter. I think they are buying because they see earnings next year of at least 50 cents per share with year over year growth of more than 100%. Even if you assume that the next two years growth isn't typical and reduce it for the next five years to say 50% per year, apply a reasonable PE to those earnings, you can see that the stock should trade to at least the mid 20s next year if the company just meets their guidance. The high short interest just adds fuel to the fire. Most of the shorts in this stock are the same idiots that shorted it in 1999 and 2000. They are living in the past and are wrong plain and simple. The stock is up 50% in 2 months, but I think that it will trade much higher and I have no interest in selling at 10 or 11. There might be more serious resistance at about 11.70, and if it breaks that the fireworks could start.

All that said, here's my plan:

1. Hold a full position as long as the stock moves up slowly and steadily like it has the last few months.

2. Sell a couple thousand shares if it spikes quickly and use that stock as a trading position.

3. As always, keep an eye on the fundamentals and sell if things don't appear to be working out like I expect.

I consider MTXX a growth stock, and it is difficult to trade growth stocks during their growth phase. Quite often they trade steadily higher with only minor and short-lived pull backs. This stock isn't going up on hype like in early 2000 when it reached 36. Fundamentals are driving the stock, and I think that it is worth even more.



To: DanZ who wrote (4913)11/19/2003 12:57:52 PM
From: StockDung  Respond to of 5582
 
KATE SMITH'S ALL-TIME RECORD - 66 Wins, 15 Losses, 3 Ties



To: DanZ who wrote (4913)11/19/2003 1:32:26 PM
From: StockDung  Respond to of 5582
 
WHERE IS 8-K? SAYS JUST ONE. VERY MATERIAL EVENT ACCORDING TO THE COMPANIES OWN SEC FILINGS.


MTXX 11/12/2003 10-Q

We may incur significant costs resulting from product liability claims


We are subject to significant liability should use or consumption of our products cause injury, illness or death. Although we carry product liability insurance, there can be no assurance that our insurance will be adequate to protect us against product liability claims or that insurance coverage will continue to be available on reasonable terms. A product liability claim, even one without merit or for which we have substantial coverage, could result in significant legal defense costs, thereby increasing our expenses and lowering our earnings. Such a claim, whether or not proven to be valid, could have a material adverse effect on our product branding and goodwill, resulting in reduced market acceptance of our products. This in turn could materially adversely affect our results of operations and financial condition.

===========================================

THE REASON FOR 8-K

Zicam Marketers Sued
Stephen Barrett, M.D.

--------------------------------------------------------------------------------

On October 14, 2003, Dennis and Debra Christensen of Almena, Michigan, filed suit against the marketers of Zicam Cold Remedy Nasal Gel , a homeopathic product claimed to "reduce the severity and duration of common cold symptoms even when treatment is started as late as the second day after onset of illness." The suit alleges that Dennis Christenson sustained permanent loss of his sense of smell following a single application of the product. Several similar cases were reported at a meeting of the American Rhinologic Society in September 2003. The case report authors state that direct application to the inner lining of the nose has long been known to produce loss of the sense of smell.

--------------------------------------------------------------------------------

UNITED STATES DISTRICT COURT
WESTERN DISTRICT OF MICHIGAN
SOUTHERN DIVISION

DENNIS CHRISTENSEN and
DEBRA CHRISTENSEN,
Plaintiffs,
vs.

MATRIXX INITIATIVES, INC., a
Delaware Corporation, formerly
known as Gumtech International,
INC., and ZICAM, LLC, formerly known
as Gel Tech, LLC an Arizona limited
Liability Company

Defendants. Case No. 4:03CV0146

Hon. Wendell Miles
Senior .U.S. District Judge

Filed October 14, 2003.

--------------------------------------------------------------------------------


William P. Webster, Jr. (P63144)
CHAMBERS, STEINER & STURM, P.L.C. Attorneys for Plaintiffs
141 East Michigan Avenue, Suite 400
Kalamazoo, MI 49007
(269) 385-4300


--------------------------------------------------------------------------------


THERE IS NO OTHER PENDING OR RESOLVED CIVIL ACTION ARISING OUT OF THE SAME TRANSACTION OR OCCURRENCE AS ALLEGED IN THE COMPLAINT


--------------------------------------------------------------------------------


COMPLAINT
AND
DEMAND FOR JURY TRIAL


--------------------------------------------------------------------------------

NOW COME the Plaintiffs, Dennis Christensen and Debra Christensen, by and through their attorneys, CHAMBERS, STEINER & STURM, P.L.C., and for their complaint against the Defendants, state as follows:

GENERAL ALLEGATIONS

1. Plaintiffs are residents of the Township of Almena, County of Van Buren, State of Michigan.

2. DEFENDANT Matrixx Initiatives, Inc., is a Delaware Corporation which conducts business in and throughout the State of Michigan.

3. Defendant Zicam, L.L.C. is an Arizona Limited Liability Company which is a wholly owned and controlled subsidiary of Matrixx Initiatives, Inc., and which conducts business in and throughout the State of Michigan.

4. All of the acts or occurrences giving rise to this complaint occurred in the Counties of Kalamazoo and Van Buren, State of Michigan.

5. Jurisdiction in this Court is based upon diversity of jurisdiction.

6. The amount in controversy exceeds $75,000.00 exclusive of interest, costs and attorney fees.

FACTUAL ALLEGATIONS

7. Plaintiffs herein reallege and incorporate by reference each and every paragraph set forth above and further state as follows:

8. Defendant Matrixx Initiatives, Inc. is engaged in the development, manufacture and marketing of over the counter pharmaceuticals, including Zicam Cold Remedy.

9. Zicam, L.L.C. is a wholly owned subsidiary of Matrixx Initiatives, Inc. and Zicam, L.L.C. produces, markets and sells Zicam Cold Remedy Nasal Gel, a patented "homeopathic" remedy.

10. Matrixx Initiatives, Inc. and Zicam, L.L.C., hereinafter collectively referred to as Defendant Matrixx, produce, develop, manufacture and market Zicam Cold Remedy Nasal Gel.

11. Zicam Cold Remedy Nasal Gel is packaged in various manners and with various delivery systems, all of which are developed, manufactured and marketed by or with the express consent of Defendant Matrixx.

12. One such version of Zicam Cold Remedy Nasal Gel is developed, marketed and manufactured by Defendant Matrixx in a nasal spray format.

13. The nasal pump by which Zicam is administered is intended to "splatter" the Zicam Cold Remedy within the nose.

14. The nasal pump utilized by Defendant Matrixx in delivering the Zicam nasal spray to the user's nose is capable of propelling the Zicam approximately ten feet.

15. Zicam Cold Remedy Nasal Spray contains divalent ionized zinc in the form of zinc gluconate, which is listed on the product's active ingredients under the trade name of "zincum gluconium 2x".

16. Zinc gluconate contains a divalent zinc ion.

17. Zinc gluconate is a chemical compound characterized as a "zinc salt".

18. If used as directed, Zicam Cold Remedy Nasal Spray delivers the Zicam Cold Remedy Gel containing zinc gluconate to the nasal membranes of the user of the product.

19. Zicam Cold Remedy is not a "drug" as that term is defined in §201 of the Federal Food, Drug and Cosmetic Act, Chapter 675, 52 Stat. 1040, 21 USC 321. .

20. Zicam Cold Remedy Nasal Spray, hereinafter also referred to as "the product", is not and never has been approved for safety and/or efficacy by the United Stated Food and Drug Administration

21. Zicam Cold Remedy's labeling has never been approved by the United States Food and Drug Administration.

22. Defendant Matrixx, as the successor corporation to Gumtech International, Inc., is liable for any negligence of Gumtech International, Inc. under the doctrine of successor liability.

Likewise, Zicam, LLC, as the successor to Gel Tech, LLC, is liable for any negligence of Gel Tech, LLC under the doctrine of successor liability.

23. Sometime during the autumn of 2001, Debra Christensen purchased a bottle of Zicam Cold Remedy Nasal Spray from a Meijer Thrifty Acres store located on M-43 in Kalamazoo County, Michigan.

24. During the month of April, 2002, Plaintiff Dennis Christensen felt a cold coming on.

25. When Plaintiff Dennis Christensen informed his wife that he felt that he was becoming sick, the Plaintiff, Debra Christensen told her husband, Dennis Christensen that she had purchased some Zicam Cold Remedy Nasal Spray and that he should use it.

26. Plaintiff Christensen then used, as directed on the packaging of the product, the Zicam Cold Remedy Nasal Spray that was purchased by his wife.

27. After applying the Zicam Cold Remedy Nasal Spray to both nostrils, Plaintiff Dennis Christensen felt an intense stinging and/or burning sensation in his nose.

28. Since this one and only use of Zicam Cold Remedy Nasal Spray, Plaintiff Dennis Christensen has totally lost his sense of smell.

29. Plaintiff, Dennis Christensen's loss of his sense of smell ("anosmia") has continued to the date of this complaint.

30. That despite medical consultations and treatments, Mr. Christensen's sense of smell has yet to return.

31. Mr. Christensen has been informed that the sense of smell is in all likelihood permanent, total and irreversible.

32. As a result of the total, irreversible loss of smell, Mr. Christensen's ability to taste has been severely diminished and his likewise permanent, total and irreversible.

33. The product Zicam Cold Remedy Nasal Spray, when used as directed by Plaintiff Dennis Christensen, caused a permanent, total and irreversible loss of one or more vital bodily functions of Plaintiff Dennis Christensen, namely, his ability to smell and taste.

34. The limitations on damages set forth in MCL 600.2946a(1) do not apply because the Defendants. injuries sustained by Plaintiffs Dennis and Debra Christensen were due to the gross negligence of Defendants.

35. Plaintiffs Dennis and Debra Christensen did not alter the product or its packaging at any time.

36. Plaintiffs Dennis and Debra Christensen did not misuse the product at any time.

37. Plaintiff Dennis Christensen was not aware that the use of the product created an unreasonable risk of personal injury. Plaintiff further did not voluntarily expose himself to any known, unreasonable risk of harm in using this product, as he was not aware, prior to his one and only use of it that it posed an unreasonable risk of personal injury.

38. Plaintiff Dennis Christensen is not a "sophisticated user" as that term is used in MCL 600.2947(4).

39. The unreasonably dangerous aspect of the product could easily be eliminated by defendants without compromising its usefulness or desirability, if any such usefulness or desirability even exists.

40. At the time of the product's manufacture and distribution, Defendant Matrixx had actual knowledge that the product was defective and that there was a substantial likelihood that the defect would cause the injury that is the basis of this cause of action; Defendant Matrixx further willfully disregarded that knowledge in the manufacture and/or distribution of this product.

41. Defendant Matrixx continues to disregard the knowledge that intranasal application of Zicam Cold Remedy Nasal Spray causes total, permanent and irreversible anosmia when used as directed.

COUNT I
DESIGN DEFECT PRODUCT LIABILITY
AGAINST DEFENDANT MATRIXX ON BEHALF OF
PLAINTIFF DENNIS CHRISTENSEN

42. The Plaintiffs herein reallege and incorporate by reference each and every paragraph set forth above, and further state as follows:

43. Defendants Matrixx Initiatives, Inc. and Zicam, L.L.C. and their predecessor entitie owed a duty to Plaintiff, Dennis Christensen, and all others similarly situated, to use due care and caution in the design of its Zicam Cold Remedy Nasal Spray to avoid unreasonable risks of injury during reasonably foreseeable uses of the product.

44. Using the product as directed on its packaging is a reasonably foreseeable use of the product.

45. The Defendants, Matrixx Initiatives, Inc. and Zicam, L.L.C. breached this duty through acts and/or omissions which include, but are not necessarily limited to, the following:

a. By designing a product intended to and instructing its users to apply Zicam Cold Remedy Nasal Spray intranasally;

b. By failing to engage in proper and adequate testing of this product and its long term effects on the sense of smell;

c. By failing to conduct an even minimal investigation into the historical and scientific evidence that relates intranasal zinc application to permanent, total and irreversible anosmia;

d. By failing to adequately warn users of the product that use of the product as directed could potentially cause permanent total and irreversible anosmia;

e. By otherwise failing to design the product in accordance with prevailing industry and scientific standards in a manner that would have eliminated unreasonable risks of injury during reasonably foreseeable uses.

46. At the time Defendants Matrixx Initiatives, Inc. and Zicam, L.L.C. designed the product, the severity of injury to users was foreseeable to Defendants.

47. At the time Defendants Matrixx Initiatives, Inc. and Zicam, L.L.C. designed the product, there was one or more reasonable alternative designs available.

48. The aforementioned available alternative designs were practicable.

49. The available practical and reasonable design alternatives would have reduced or completely eliminated the foreseeable risk of harm posed by the nasally introduced Zicam Cold Remedy.

50. Failure to use the available, practical and reasonable alternative designs rendered the product not reasonably safe for its intended use.

51. As a direct and proximate result of Defendants Matrixx Initiatives, Inc. and Zicam, L.L.C.'s breach of the aforementioned duties and negligence described above, the Plaintiff, Dennis Christensen, suffered complete, total, permanent and irreversible loss of his sense of smell.

52. As a direct and proximate result of Defendants Matrixx Initiatives, Inc. and Zicam, L.L.C.'s breach ofthe aforementioned duties and negligence described above, the Plaintiff, Dennis Christensen, suffered a permanent and irreversible severely diminished sense of taste.

53. As a direct and proximate result of the negligence of the Defendants Matrixx Initiatives, Inc. and Zicam, 1.1.C., and the injuries suffered by the Plaintiff, Dennis Christensen, the

Plaintiff, Dennis Christensen, has suffered damages which are continuing in nature and include, but are not necessarily limited to, the following:

a. Complete, total, permanent and irreversible loss of the sense of smell;

b. Permanent and irreversible diminution of the sense of taste;

c. The need to undergo several fruitless medical procedures and treatments;

d. Mental and emotional distress;

e. Mortification and humiliation;

f. Physical pain and suffering;

g. Medical expenses;

h. Loss of enjoyment of everyday activities and severely diminished quality of life given the fact that two of his five senses are gone forever;

i. Increased susceptibility to risks generally avoidable by a person with an intact sense of smell;

j. Other damages not specifically identified above.

WHEREFORE, the Plaintiff, Dennis Christensen, respectfully requests that this Honorable Court grant him judgment against Defendants Matrixx Initiatives, Inc. and Zicam, L.l.C., in whatever amount above Seventy-five Thousand Dollars ($75,000.00) he is found to be entitled, together with interest, costs and attorney fees.

COUNT II
LOSS OF CONSORTIUM CLAIM MADE BY
PLAINTIFF DEBRA CHRISTENSEN

54. The Plaintiffs herein reallege and incorporate by reference each and every paragraph set forth above, and further state as follows:

55. Plaintiff, Debra Christensen, is the spouse of Plaintiff, Dennis Christensen.

56. As a direct and proximate result of the injuries to Plaintiff, Dennis Christensen, proximately caused by the Defendants named herein, Plaintiff, Debra Christensen has been deprived of the support, comfort, society and companionship of her husband, Dennis Christensen, and those other pleasures and rights growing under the marriage relationship known as consortium.

WHEREFORE, the Plaintiff, Debra Christensen, respectfully requests that this Honorable Court grant her judgment against all Defendants, in whatever amount above Seventy-five Thousand Dollars ($75,000.00) she is found to be entitled, together with interest, costs and attorney fees.

DEMAND FOR JURY TRIAL

NOW COME the Plaintiffs, Dennis Christensen and Debra Christensen, by and through their attorneys, CHAMBERS, STEINER & STURM, P.L.C., and hereby demand a trial by jury.

Respectfully submitted,

William P. Webster, Jr.

Dated: October 13, 2003


--------------------------------------------------------------------------------

HomeoWatch Home Page

This article was posted on November 4, 2003



To: DanZ who wrote (4913)11/19/2003 10:53:50 PM
From: StockDung  Respond to of 5582
 
cochraneconsumer.com



To: DanZ who wrote (4913)11/24/2003 9:13:59 PM
From: StockDung  Respond to of 5582
 
hmmm, wonder is this is zicam Davidson?->"If you do the same workout every day, you're going to plateau. It's the same with your diet," says R. Steven Davidson, who holds a Ph.D. in biochemistry from Columbia University. "By changing up the amount of carbs you consume per day [while maintaining an exercise regimen], you create an uncertainty that boosts your body's metabolic rate." To make it easy for you, we've provided specific meal plans for both high- and low-carb days." mensfitness.com

===============================================
mensfitness.com

Eat Carbs to Lose Fat

That's right. Burn fat fast (without starving) with our easy carb-rotation plan.

Originally featured in:
Men's Fitness April, 2001

Written by: Steve Stiefel Photos by: David Roth/Stone


p a g e 1 | 2

Insanity has been defined as expecting different results from repeating the same behavior. Professional athletes take this concept into account when trying to make improvements in their performance. When Andre Agassi's ATP Tour ranking plummeted from No. 1 to No. 110 several years back, he knew he had to do more than just endlessly hit balls across the net if he wanted to regain his previous dominance. After embarking on a cross-training and weightlifting program, he eventually made it back to the top of the tennis world.

Too many carbs make you fat, and too few make you tired. What's the answer? Rotation.


You may have made a similar adjustment with regard to your weight-training or cardio program. However, this acquired sanity tends to take a leap out the window when it comes to nutrition. Many guys go on low-calorie crash diets to shed body fat, only to balloon back up when they revert back to their previous eating mode. If you've been working out regularly but haven't been able to shrink a recalcitrant gut, try the simple strategy of rotating the amount of carbs you eat on a daily basis. Simply put, eat different amounts of carbs on certain days of the week to create an environment in which your body is more likely to tap into body-fat stores for energy.

"If you do the same workout every day, you're going to plateau. It's the same with your diet," says R. Steven Davidson, who holds a Ph.D. in biochemistry from Columbia University. "By changing up the amount of carbs you consume per day [while maintaining an exercise regimen], you create an uncertainty that boosts your body's metabolic rate." To make it easy for you, we've provided specific meal plans for both high- and low-carb days.

The Low-Carb Depression
Low-calorie diets usually fail for a couple of reasons. First, they tend to reduce your calories so low that you just can't put up with the hunger pangs and withdrawal for very long. Second, such diets actually reduce your metabolic rate, making you burn calories slower than you did before. By drastically cutting calories, you send your body the message that it needs to survive on less, so it reduces the amount it burns. When you return to your normal eating patterns, you've turned your body into a fat-storing machine, and you start to blubber back up in the precise places where you had lost body fat, often surpassing previous fat stores.

"Carbohydrates are the preferred fuel in most tissues of the body," says Lyle McDonald, author of The Ketogenic Diet. "When carbohydrates are available, they're burned first, instead of fat. Basically, the more carbohydrates you eat, the less fat you burn; the fewer carbohydrates you eat, the more body fat you burn."

But low-carb diets have limitations; you may begin to feel sluggish and depleted, especially when you work out, and you may not be able to maintain that level of deprivation. You may also become agitated, anxious and depressed. Carbohydrates give you the physical and mental energy you need to work out, and this creates a Catch-22: If you eat a lot of carbohydrates, you keep your muscles primed for training, but you won't eliminate body fat. If you drastically reduce carbohydrate intake, you deplete your muscle-glycogen stores, which makes for poor progress while training. How do you have your cake and eat it, too? Rotate those carbs, man.

Benefits of Cycling Carbs
To lose body fat and keep it off for good, you must accomplish two seemingly contradictory objectives: 1) reduce calories below the level you need for bodyweight maintenance, and 2) provide your body with all the energy and nutrients it needs to function at full capacity. A nutrition plan that has you cycling high- and low-carbohydrate intake throughout the week helps you do both. "Carbohydrate cycling allows the benefits of fat-burning while still maintaining high-intensity exercise performance and results," McDonald says.

On days when you eat fewer carbs, your body taps into fat stores for energy. On days when you consume more carbs, you'll be refueling your muscles, keeping you primed for your workouts over the next few days. The eating program outlined below provides you with virtually the same amount of calories each day. On low-carb days, increase your consumption of protein and healthy fats; on high-carb days, decrease these foods. The only stipulation is that you must consume 10 percent to 15 percent fewer calories than you need for maintenance, because you can't lose body fat if you're taking in more calories than you're burning.

Real-Guy Rotation Plan
This diet plan is designed for people who live in the real world, i.e., you. We don't expect you to spend all your time counting and weighing every gram of food that passes your lips. The idea is simply to keep your carbohydrates low on Monday, Tuesday, Thursday and Friday, and to elevate them on Wednesday, Saturday and Sunday. This rotation seems to best fit most people's schedules, but feel free to change up the days to better suit your lifestyle.

On low-carb days, eat no more than 150 grams of carbs. We've outlined full nutrition plans for two days to give you an indication of the types and quantities of foods to consume. On the "off" days, eat around 300 grams of carbs. A little cheating is okay, and even encouraged on high-carb days, because that helps keep your body in a state of metabolic confusion, and keeps fat-burning channels open. Use our sample menus to help create combinations that appeal to you and your lifestyle. If you put particular emphasis on decreasing your carbs on the down days while sticking to your exercise regimen, you'll begin to see that stubborn body fat finally disappear. 1 | p a g e 2




Steve Stiefel orders a protein-heavy breakfast every morning, but the deli never gets it right.





mensfitness.com



To: DanZ who wrote (4913)11/24/2003 9:30:04 PM
From: StockDung  Respond to of 5582
 
Men's Fitness, March, 1999, by R. Steven Davidson, Steve StiefelContinued from page 3

PSA cost: $30 to $50.

Physical prostate exam: Included in general physical.

Saw palmetto: About $13 for 60 500-milligram pills.

Covered by HMO? Most HMOs will cover the costs of a physical prostate exam and PSA exam once a year, although you should get approval beforehand to ensure coverage if you're under the age of 40.

R. Steven Davidson, PhD, is CEO of Biotem Cytotechnologies, a nonprofit institute specializing in disease and human-performance research. Steve Stiefel is staff writer at Flex magazine.

COPYRIGHT 1999 Weider Publications
COPYRIGHT 2000 Gale Group

216.239.57.104



To: DanZ who wrote (4913)11/24/2003 9:31:38 PM
From: StockDung  Respond to of 5582
 
says R. Steven Davidson, who holds a Ph.D. in biochemistry from Columbia University." Message 19533831



To: DanZ who wrote (4913)11/24/2003 9:38:20 PM
From: StockDung  Respond to of 5582
 
"who holds a Ph.D. in biochemistry from Columbia University." Message 19533869



To: DanZ who wrote (4913)11/24/2003 9:40:14 PM
From: StockDung  Respond to of 5582
 
O, Columbia! the gem of the ocean,
The home of the brave and the free,
The shrine of each patriot's devotion,
A world offers homage to thee.
Thy mandates make heroes assemble
When Liberty's form stands in view;
Thy banners make tyranny tremble

When borne by the Red, White and Blue!
When borne by the Red, White and Blue!
When borne by the Red, White and Blue!
Thy banners make tyranny tremble
When borne by the Red, White and Blue!

The wine cup, the wine cup bring hither,
And fill you it true to the brim!
May the wreaths they have won never wither,
Nor the star of their glory grow dim!
May the service united ne'er sever,
But they to their colors prove true!

The Army and Navy forever,
Three cheers for the red, white and blue,
Three cheers for the red, white and blue,
Three cheers for the red, white and blue,
The Army and Navy forever,
Three cheers for the red, white and blue



To: DanZ who wrote (4913)11/25/2003 5:16:20 PM
From: StockDung  Respond to of 5582
 
MTXX November 2003 Short Interest 580,276 Percentage Change (44.90) Average Daily Share Volume 235,000
Days to cover 2.46

Good, now that the squezzzzzzzzzzze is out of the way we can get back to talking about the company.

PREVIOUS MONTHS

Matrixx Initiatives Inc. Nasdaq-NM

Settlement Date Short Interest Avg Daily
Share Volume Days to Cover

Oct. 15, 2003 1,053,079 79,625 13.23
Sep. 15, 2003 928,583 51,515 18.03
Aug. 15, 2003 897,418 39,586 22.67
Jul. 15, 2003 829,501 38,458 21.57
Jun. 13, 2003 738,333 39,882 18.51
May 15, 2003 678,727 52,682 12.88
Apr. 15, 2003 455,671 17,951 25.38
Mar. 14, 2003 384,803 28,436 13.53
Feb. 14, 2003 359,968 20,993 17.15
Jan. 15, 2003 340,724 19,127 17.81
Dec. 13, 2002 311,381 23,989 12.98
Nov. 15, 2002 281,765 22,354 12.60

Data source: The Nasdaq Stock Market, Inc.



To: DanZ who wrote (4913)11/25/2003 10:01:46 PM
From: StockDung  Respond to of 5582
 
Gunnallen almost 50% of total MTXX volume in October nasdaqtrader.com

Remember when the Gunnallen guy posted on Yahoo only 20 brokers in the firm had clients in the stock?

Wonder how many Donald J. Gunn had?



To: DanZ who wrote (4913)11/26/2003 10:27:42 AM
From: StockDung  Read Replies (1) | Respond to of 5582
 
Schering-Plough and ViroPharma Enter Into Agreement for New Intranasal Formulation of Pleconaril
Tuesday November 25, 12:41 pm ET

KENILWORTH, N.J. and EXTON, Penn., Nov. 25 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP - News) and ViroPharma Incorporated (Nasdaq: VPHM - News) today announced that the companies have entered into an option agreement to license ViroPharma's intranasal formulation of the antiviral compound pleconaril to Schering-Plough for the treatment of the common cold in the United States and Canada. The new intranasal formulation of pleconaril represents an optimized delivery approach for this compound.


Under terms of the agreement, Schering-Plough will pay ViroPharma an upfront option fee of $3 million. ViroPharma will then conduct a series of clinical studies designed to evaluate the antiviral activity, safety and other performance characteristics of the new intranasal pleconaril formulation. Results from these studies are scheduled to be available in mid-2004.

Based on its assessment of the product's performance in the characterization studies, Schering-Plough has the option to trigger a full license agreement with ViroPharma, under which it would assume responsibility for all future development and commercialization of intranasal pleconaril in the United States and Canada. If Schering-Plough chooses to exercise its option, ViroPharma will receive an initial license fee of $10 million and Schering-Plough will purchase ViroPharma's existing inventory of bulk drug substance for an additional pre-determined fee. ViroPharma would also be eligible to receive additional milestone payments upon achievement of certain targeted events as well as royalties on Schering-Plough's sales of intranasal pleconaril in the licensed territories.

"We are delighted that we've entered into this agreement with Schering- Plough Corporation," said Mark McKinlay, ViroPharma's Vice President of Research and Development. "We hope to demonstrate that this formulation can deliver significantly more drug to the site of active common cold infection than the oral formulation, while limiting its systemic exposure and, thereby, minimizing the risk of drug interactions," he said.

"We look forward to working with ViroPharma on this opportunity and to bringing Schering-Plough's extensive expertise in respiratory diseases to this program," said Thomas P. Koestler, executive vice president, worldwide regulatory affairs, worldwide research quality assurance and project management, Schering-Plough Research Institute.

To date, oral pleconaril has been studied in more than 5,000 patients in clinical trials for the treatment of the common cold and in more than 700 patients as part of a compassionate use program in patients who have serious or life-threatening picornavirus infections. In 2002, the FDA issued a "not approvable" letter for an oral tablet formulation of pleconaril for treatment of the common cold in adults.

In 1995, ViroPharma licensed rights to develop and commercialize intranasal pleconaril in the United States and Canada from Sanofi-Synthelabo.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking" statements concerning, among other things, the commercialization and market potential of intranasal pleconaril. Forward- looking statements are subject to substantial risks and uncertainties and actual results may differ materially from forward-looking statements. These risks and uncertainties include the regulatory process for the approval of products, general market and economic factors, competitive product development and marketing, product availability, market acceptance of new products, and federal and state regulations and legislation. For further details and a discussion of these and other risks and uncertainties that may impact Schering-Plough's forward looking statements, see the company's current and future Securities and Exchange Commission filings, including the third quarter 2003 10-Q.

VIROPHARMA FORWARD LOOKING STATEMENT: This press release contains forward- looking statements that involve a number of risks and uncertainties. These forward-looking statements include those relating to our plan to conduct studies designed to evaluate the antiviral activity, safety and other performance characteristics of intranasal pleconaril for the treatment of the common cold; statements expressing our expectation that data from those studies should be available in the second quarter of 2004; statements expressing our expectation that an intranasal formulation of pleconaril would increase the amount of drug delivered to the site of infection; and statements expressing our belief that an intranasal formulation of pleconaril would limit systemic exposure and thereby reduce the risk of drug interactions. Conducting clinical trials for investigational pharmaceutical products are subject to risks and uncertainties. As a result, our actual results could differ materially from those results expressed in, or implied by, this press release. There can be no assurance that we will, or will be able to, initiate or conclude clinical studies with pleconaril in the timeframe that we expect, or at all; that an intranasal formulation of pleconaril will limit systemic exposure and thereby reduce the risk of drug interactions; or that Schering- Plough will ultimately exercise its option to continue with the development and commercialization of intranasal pleconaril and enter into a license agreement with ViroPharma for intranasal pleconaril. These factors, and other factors, including, but not limited to those described in ViroPharma's most recent annual report on Form 10-K filed with the Securities and Exchange Commission, could cause future results to differ materially from the expectations expressed in the answers to this press release. The forward- looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward- looking statements.

Schering-Plough is a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products worldwide.

ViroPharma Incorporated is committed to the commercialization, development and discovery of antiviral pharmaceuticals. ViroPharma is currently focused on drug development of maribavir for the prevention and treatment of cytomegalovirus infection in transplant patients, and drug development and discovery activities in hepatitis C, biodefense and emerging disease initiatives. ViroPharma also is developing an intranasal formulation pleconaril for the treatment of the common cold, and is considering the development of an oral formulation of pleconaril to treat patients suffering from severe or life-threatening picornavirus infections.

--------------------------------------------------------------------------------
Source: Schering-Plough Corporation